Company
Clearbridge Health Limited
SGX Catalist:1H3
Operates medical clinics and diagnostic services across Singapore, the Philippines and Hong Kong, including imaging, general health screening and vaccination. Its longevity relevance is limited and indirect: it is a clinic and screening operator, not a company developing ageing-biology interventions or aging-specific biomarker panels. The relevant exposure is preventive health screening infrastructure in Southeast Asia, which sits adjacent to the longevity clinic market. Financial condition is weak: FY2025 revenue of S$9.93m was flat year on year while net loss widened to S$12.91m, and the shares trade at S$0.001 on the SGX Catalist board with a market capitalisation of roughly S$6.4m. Include only with that caveat.
At a glance
- Listing
- SGX Catalist:1H3
- Category
- Diagnostics
- Headquarters
- Singapore
- Market cap
- Approximately S$6.4m (July 2026, stockanalysis.com; share price S$0.001, 6.44bn shares outstanding)
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Singapore
- Recent inflection
- FY2025 results (year ended 31 December 2025, adopted at the AGM on 23 April 2026) showed revenue of S$9.93m, essentially flat year on year, with net loss widening to S$12.91m, roughly 258% worse than 2024. The company has since continued issuing shares at sub-cent prices, including an allotment of 2.1m shares at S$0.0018 in June 2026.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | SGX Catalist |
| Ticker | SGX Catalist:1H3 |
| Secondary listing | None |
| Market cap | Approximately S$6.4m (July 2026, stockanalysis.com; share price S$0.001, 6.44bn shares outstanding) |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Singapore
- Website
- stockanalysis.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
FY2025 results (year ended 31 December 2025, adopted at the AGM on 23 April 2026) showed revenue of S$9.93m, essentially flat year on year, with net loss widening to S$12.91m, roughly 258% worse than 2024. The company has since continued issuing shares at sub-cent prices, including an allotment of 2.1m shares at S$0.0018 in June 2026.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Clearbridge Health (SGX:1H3) Stock Price & Overview · StockAnalysis.com
- Clearbridge Health Latest Announcements (SGX:1H3) · SGinvestors.io
Every entity profile on variis is sourced. Not investment advice.